Alamar Biosciences, Inc. (ALMR)
| Market Cap | 1.69B |
| Revenue (ttm) | 74.21M +195.2% |
| Net Income | -29.82M |
| EPS | -1.07 |
| Shares Out | 68.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 707,380 |
| Open | 24.45 |
| Previous Close | 24.27 |
| Day's Range | 24.28 - 24.98 |
| 52-Week Range | 21.50 - 25.03 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 23, 2026 |
About ALMR
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnosti... [Read more]
News
Alamar Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
FREMONT, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (“Alamar”), a leader in Precision Proteomics dedicated to advancing the early detection of disease, today announced the clo...
Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ
SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ Stock Exchang...
Alamar Biosciences valued at $1.5 billion as shares jump in Nasdaq debut
Shares of Alamar Biosciences jumped 33% in their Nasdaq debut on Friday, valuing the protein biomarker detection platform at $1.53 billion.
Alamar Biosciences Announces Pricing of Upsized Initial Public Offering
Alamar Biosciences, Inc., a leader in precision proteomics dedicated to advancing the early detection of disease...
Protein biomarker detection platform Alamar Biosciences files for a $100 million IPO
Alamar Biosciences, which provides a protein biomarker detection platform for disease detection research, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Alamar Biosciences IPO Registration Document (S-1)
Alamar Biosciences has filed to go public with an IPO on the NASDAQ